JN.1 booster refines existing COVID-19 antibody defenses in people

The immune system did not start from zero. After a JN.1-adapted mRNA booster, researchers in Hannover and Göttingen found that previously immunized people mainly redeployed their existing memory B cells — immune cells that remember earlier encounters — to recognize the newer variant. The study reports improved antibody binding and neutralization against JN.1 and closely related subsequent variants.

At first, the researchers detected only B cells that recognized the earlier Wu01 variant exclusively or were cross-reactive against both Wu01 and JN.1. B cells specific to JN.1 appeared more slowly, reaching their peak 21 days after vaccination. That timing showed that the JN.1-specific response emerged later.

The team from TWINCORE, Hannover Medical School and the German Primate Center used single-cell RNA sequencing and functional tests of monoclonal antibodies — laboratory-made copies of one antibody — to track the change. They found that somatic hypermutation, a natural process that fine-tunes antibody genes, helped existing memory B cells bind JN.1 more effectively and neutralize it more strongly.

The finding matters because mutations in the SARS-CoV-2 genome can reduce the effectiveness of RNA-based vaccines, which consequently have to be adapted regularly. The study suggests that an updated booster can reshape immune memory toward a new variant, while activation of naive B cells does not appear to be the dominant mechanism.

So what changes in practice? For people whose immune responses have already been shaped by vaccination or infection, a variant-adapted booster may improve the quality of defenses they already possess, rather than having to build a new response from scratch. The researchers measured antibodies and B cells, not real-world protection against infection or severe disease, so the result is a map of the immune response — not a clinical guarantee.